文献速递肿瘤 PET/CT神经核医学

基于异柠檬酸脱氢酶1突变和PET/CT上18F-FDG摄取预测脑胶质瘤患者总生存期

Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas.
PubMed 文献 · Clin Nucl Med · 2018-01-01

这项回顾性研究纳入59例脑胶质瘤患者,分析PET/CT的G/C比值与IDH1突变的相关性及对总生存期的预后价值。IDH1突变型肿瘤G/C比值显著低于野生型(0.73 vs 1.14,P=0.004),IDH1突变和G/C比值均为总生存期的显著预后因素,分类回归树模型识别出3个风险组且组间总生存期存在显著差异。

要点

  • IDH1突变型胶质瘤的G/C比值显著低于IDH1野生型(0.73 vs 1.14,P=0.004)。
  • 多因素分析中IDH1突变和G/C比值对总生存期均有显著意义。
  • 分类回归树识别3个风险组,组1至组3平均总生存期依次为37.0、28.6、20.7个月。

核心结论

  • IDH1突变型胶质瘤的18F-FDG摄取显著低于IDH1野生型胶质瘤。
  • IDH1突变是识别预后最佳患者的最重要因素,而FDG摄取增高为预测IDH1野生型胶质瘤患者较差总生存期提供额外预后信息。

研究设计与样本

  • 回顾性研究,纳入59例胶质瘤患者,分析PET/CT上肿瘤SUVmax与对侧皮质SUVmean之比(G/C比值)与IDH1突变的相关性,并采用Cox比例风险模型和分类回归树模型评估预后因素。

主要发现

  • IDH1突变型肿瘤的平均G/C比值为0.73,IDH1野生型为1.14,两者差异显著(P=0.004)。
  • 多因素分析中IDH1突变和G/C比值对总生存期均有显著意义。
  • 分类回归树模型识别3个风险组:组1为IDH1突变(风险比0.2),组2为G/C比值≤0.8且IDH1野生型(风险比0.83),组3为G/C比值>0.8且IDH1野生型(风险比1.9),总体P<0.001。
  • 平均总生存期组1为37.0个月、组2为28.6个月、组3为20.7个月,组间差异显著(组1 vs 组2:P=0.023;组2 vs 组3:P=0.049;组1 vs 组3:P<0.001)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This retrospective study aimed to correlate F-FDG uptake on PET/CT with isocitrate dehydrogenase enzyme isoform 1 (IDH1) mutation in patients with cerebral gliomas. Hierarchical interactions between factors affecting overall survival (OS) were also examined. METHODS: In 59 patients with glioma, the ratio of the SUVmax of a glioma to the SUVmean of the contralateral cortex (G/C ratio) on F-FDG PET/CT and the presence of IDH1 mutation were correlated. The prognostic value of clinicopathologic factors and G/C ratio for OS were assessed using a Cox proportional hazards model and classification and regression tree models. RESULTS: The mean G/C ratio of IDH1-mutant tumors was significantly lower than that of IDH1 wild-type tumors (0.73 vs 1.14, P = 0.004). In multivariate analysis, IDH1-mutant and G/C ratio were significant for OS. The classification and regression tree modeling identified 3 risk groups for OS (group 1: IDH1 mutant [hazard ratio, 0.2]; group 2: G/C ratio ≤0.8 with IDH1 wild type [hazard ratio, 0.83]; group 3: G/C ratio >0.8 with IDH1 wild type [hazard ratio, 1.9]) (overall P < 0.001). The mean OS was 37.0 months in group 1, 28.6 months in group 2, and 20.7 months in group 3, respectively, showing significant differences among the groups (group 1 vs group 2: P = 0.023, group 2 vs group 3: P = 0.049, group 1 vs group3: P < 0.001). CONCLUSIONS: F-FDG uptake of IDH1-mutant gliomas was significantly lower than that of IDH1 wild-type gliomas. IDH1 mutation was the most important factor in identifying patients with the best prognosis, whereas increased F-FDG uptake provided additional prognostic information for predicting poor OS among patients with IDH1 wild-type gliomas.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Kim D, Kim S, Kim SH, et al. Prediction of Overall Survival Based on Isocitrate Dehydrogenase 1 Mutation and 18F-FDG Uptake on PET/CT in Patients With Cerebral Gliomas. Clin Nucl Med. 2018. PMID: 29485450. doi:10.1097/RLU.0000000000002006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。